Which Weight Management Injection Suits Your Needs?
Wegovy vs Mounjaro Dosage: Understanding the Key Differences
The primary distinction in wegovy vs mounjaro dosage lies in their escalation schedules and active ingredients. Wegovy contains semaglutide, a GLP-1 receptor agonist, following a 5-step dose escalation: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist, with a 6-step escalation: 2.5mg (weeks 1-4), 5mg (weeks 5-8), 7.5mg (weeks 9-12), 10mg (weeks 13-16), 12.5mg (weeks 17-20), and 15mg maintenance from week 21.
This wegovy vs mounjaro dosage comparison reveals fundamental differences in approach and timeline. Wegovy reaches its maintenance dose one month earlier than Mounjaro, potentially offering faster stabilisation for some patients. However, Mounjaro's dual receptor mechanism may provide different appetite control benefits through its combined GIP and GLP-1 action. Both prescription-only medicines require careful dose escalation to minimise gastrointestinal side effects, and neither can skip doses during the escalation phase.
Wegovy vs Mounjaro Dosage Pricing: Complete Cost Breakdown
Understanding the financial commitment for each wegovy vs mounjaro dosage schedule helps inform your treatment choice. Wegovy pricing at EverydayMeds starts with 0.25mg at £79.99, progressing to 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), and maintenance 2.4mg (£209.99). Our Getting Started bundles offer convenience: the Intro Duo (0.25mg & 0.5mg) costs £169.99, whilst the Progress Trio (0.5mg, 1mg & 1.7mg) is £369.99. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices.
Mounjaro follows a different pricing structure due to its extended wegovy vs mounjaro dosage timeline, though both treatments are available through our streamlined ordering process. The longer escalation period means additional monthly costs before reaching maintenance, but also allows for more gradual adjustment. Our clinical team, operating under GPhC registration #9012878, can discuss the financial implications of each treatment during your assessment. Both medications represent significant monthly investments, making the choice between their dosing schedules an important financial consideration alongside clinical factors.
Clinical Evidence Comparing Wegovy vs Mounjaro Dosage Effectiveness
The STEP trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the pivotal STEP 1 trial (Wilding et al., NEJM, 2021). The STEP 5 trial showed sustained weight loss of approximately 15.2% at two years, indicating the effectiveness of the wegovy vs mounjaro dosage schedule over extended periods. These results were achieved following the complete dose escalation protocol, emphasising the importance of adhering to the prescribed dosing timeline.
Mounjaro's clinical trials used different methodologies and patient populations, making direct wegovy vs mounjaro dosage comparisons challenging. Both treatments demonstrated significant weight management benefits when used alongside reduced-calorie diets and increased physical activity, as required by their MHRA licensing conditions. The choice between dosing schedules often depends on individual tolerance, lifestyle factors, and prescriber recommendations rather than head-to-head efficacy data.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a naturally occurring hormone that regulates appetite and food intake. When injected weekly using the FlexTouch pen system, semaglutide binds to GLP-1 receptors in the brain's appetite centres, particularly the hypothalamus, promoting feelings of fullness and reducing food cravings. This mechanism explains why the wegovy vs mounjaro dosage escalation is essential – gradually increasing doses allows your body to adapt to enhanced satiety signals without overwhelming gastrointestinal side effects. The medication also slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged feelings of satisfaction after smaller meals. Additionally, Wegovy may influence food reward pathways, potentially reducing the psychological drive to eat high-calorie foods. This comprehensive approach to appetite regulation makes adherence to the prescribed dosing schedule crucial for optimal therapeutic benefit.
EverydayMeds Ordering Process: From Assessment to Delivery
Our streamlined process begins with a 3-minute online clinical assessment, covering your medical history, current medications, and weight management goals to determine suitability for either treatment in the wegovy vs mounjaro dosage comparison. UK-registered prescribers review your assessment within 3 working days (or 24 hours with express service), ensuring appropriate selection between the different dosing protocols. Once approved, your prescription-only medicine is dispatched for next-day delivery using temperature-controlled, cold-chain logistics to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) handles all aspects of dispensing, from initial assessment through ongoing prescription management and dose escalation guidance. The process includes clear instructions for injection technique, storage requirements, and scheduling your next dose increase according to your chosen treatment protocol. Ongoing support ensures smooth progression through whichever wegovy vs mounjaro dosage schedule your prescriber recommends.
Storage and Practical Considerations for Wegovy vs Mounjaro
Storage requirements present another practical factor in the wegovy vs mounjaro dosage decision, particularly for frequent travellers or those with limited refrigeration access. Wegovy pens must be stored in the refrigerator at 2-8°C before first use but can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, offering significant flexibility for travel and daily use. Mounjaro pens, whilst also requiring refrigeration before first use, can only remain at room temperature for 21 days, making Wegovy more convenient for extended trips or irregular schedules. Both medications use pre-filled, single-use pens – Wegovy employs Novo Nordisk's FlexTouch system, whilst Mounjaro uses Lilly's KwikPen technology. The wegovy vs mounjaro dosage schedules also affect storage planning, with Wegovy requiring 5 different pen strengths during escalation compared to Mounjaro's 6 different doses. Both treatments require careful dose tracking to ensure proper escalation timing and avoid medication errors.
Dual vs Single Receptor Targeting in Wegovy vs Mounjaro Dosage
The fundamental difference between these treatments lies in their receptor mechanisms, which directly influences the wegovy vs mounjaro dosage requirements and therapeutic approach. Wegovy targets GLP-1 receptors exclusively, providing focused appetite suppression and gastric emptying delay through this single pathway. This targeted approach allows for the established 5-dose escalation protocol, with each increase building upon the previous dose's GLP-1 activation. Mounjaro's tirzepatide targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, creating a dual agonist effect that may influence appetite control through multiple pathways.
This dual mechanism necessitates Mounjaro's more complex wegovy vs mounjaro dosage schedule, with 6 escalation steps allowing gradual adaptation to both receptor activations. The GIP component may provide additional metabolic benefits beyond traditional GLP-1 effects, though this comes with increased dosing complexity and extended escalation timeline. Understanding these mechanistic differences helps explain why neither treatment can be directly substituted for the other without complete dose re-evaluation. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to help determine which receptor approach and dosing schedule aligns best with your individual needs and treatment goals.
Making Your Choice: Expert Guidance for Wegovy vs Mounjaro Dosage Selection
Selecting between these wegovy vs mounjaro dosage protocols requires professional medical guidance, considering factors beyond simple weight loss goals including your medical history, lifestyle constraints, injection preferences, and budget considerations. Our clinical assessment evaluates your individual circumstances, from previous weight management attempts to current medications that might interact with either treatment option. The wegovy vs mounjaro dosage timeline differences – 16 weeks to maintenance versus 20 weeks – may influence your choice based on how quickly you prefer to reach therapeutic doses. Remember that both treatments are prescription-only medicines requiring ongoing medical supervision, with regular check-ins to monitor progress and adjust treatment as needed. Whether you choose Wegovy's focused GLP-1 approach or Mounjaro's dual receptor targeting, EverydayMeds provides comprehensive support throughout your treatment journey, from initial assessment through maintenance dosing and beyond. Start your clinical assessment today using code FIRST40 for new customers, and take the first step toward evidence-based weight management with either treatment option available at https://everydaymeds.co.uk/collections/weight-loss.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
